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ABSTRACT 
O@ectives: To characterize mupirocin-resistant methicillin-resis- 
tant Sta,oby/ococcus aureus (MRSA) isolated from patients in 
a burn unit by pulsed-field gel electrophoresis and plasmid 
contents. 
Methods: A total of 53 methicillin-resistant S. aureus, consist- 
ing of 48 mupirocin-resistant and 5 mupirocin-susceptible 
MRSA were compared by plasmid content and pulsed-field gel 
electrophoresis of Sma I digested genomic DNA. 
Results: Of the 48 mupirocin-resistant isolates, 39 expressed 
high-level, and 9 expressed low-level mupirocin resistance. 
Plasmids were detected in all of the 53 isolates; however, only 
the high-level mupirocin-resistant isolates contained a 38 kb- 
conjugative plasmid that encoded high-level mupirocin resis- 
tance. Pulsed-field gel electrophoresis divided the isolates into 
four patterns designated types I to IV Forty-three isolates con- 
sisting of 34 high-level, 5 low-level mupirocin-resistant and 4 
mupirocin-susceptible isolates defined the type-l pattern. Eight 
isolates, five high-level and three low-level mupirocin-resistant 
isolates had the type-11 pulsed-field pattern. The type-Ill and 
type-IV pulsed-field patterns consisted of a single isolate each. 
The type-l and type-11 pulsed-field patterns were related and 
only differed by four Sma I bands. 
Conclusions: Results of typing the mupirocin-resistant MRSA 
from the burn unit with pulsed-field gel electrophoresis indi- 
cated that closely related MRSA clones previously circulating 
in the unit had acquired a high-level mupirocin-resistant plas- 
mid, and spread aided by mupirocin use. 
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Since its introduction for clinical use in the United King- 
dom in 1985, mupirocin (Bactroban, SmithKline Beecham, 
Rixensart, Belgium) has become available in more than 90 
other countries worldwide.’ It has been used for the treat- 
ment of different types of skin infections and as pro- 
phylaxis before skin surgery.2-9 Mupirocin has been 
particularly useful in the elimination of nasal carriage of 
methicillin-resistant StaphyZococcus aureus (MRSA) in 
patients and health care workers,iO-l3 thereby serving as 
an important agent in the control of MRSA outbreaks. 
However, as its use has increased worldwide, mupirocin 
resistance has also emerged and is increasing.14-21 
Mupirocin resistance has been attributed to prolonged 
use of the antibiotic in some instances,16,22 although resis- 
tance has also been found in coagulase-negative staphy- 
lococci isolated long before mupirocin was available for 
clinical use.23 Mupirocin resistance can be low level (min- 
imum inhibitory concentration [MIC] 8-256 mg/L) or 
high-level (MIC > 512 mg/L). The high-level resistance 
(mupH) is clinically significant, often resulting in treat- 
ment failures.’ High-level mupirocin resistance is encoded 
by plasmid-borne mupA genes, whereas genes with low- 
level mupirocin resistance (mupL) are located on the bac- 
terial chromosome.’ Isolates expressing mupL carry 
mutations in the host’s isoleucyl-tRNA synthetase (IRS), 
whereas isolates expressing mupH contain two bio- 
chemically distinct IRS: a native mupirocin-sensitive IRS 
plus an additional enzyme that is not sensitive to inhibi- 
tion by mupirocin.24 
The burn unit at Ibn Sina Hospital, Kuwait, is a 70- 
bed special facility for treating burn patients of all ages 
and sexes. It is the only such facility for the state of 
Kuwait. It has an intensive care unit with 12 beds. The 
bed occupancy in the burn unit is 70 to 100%. Mupirocin 
was introduced for clinical use in this facility in 1992 and 
has been used consistently since then for the treatment 
of MRSA infections or for the elimination of nasal MRSA 
carriage. Both the nasal and skin preparations are avail- 
able and are administered to the patients according to 
the guidelines provided by the manufacturer.25 A study of 
395 staphylococci isolated between April 1994 and May 
1995 after more than 2 years of mupirocin use in the 
unit failed to detect mupH in any of the S. aureus iso- 
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lates.Z6 However, 5% of them expressed mupL, and one 
isolate of Staphylococcus haemolyticus expressed 
mupH.*” It was at that time recommended that, although 
the incidence of mupirocin resistance was low, MRSA iso- 
lated from the burn unit should be tested routinely for 
mupirocin resistance, so that any resistant isolates could 
be detected early and to facilitate the early institution of 
infection control measures. No further high-level 
mupirocin staphylococci were isolated in the burn unit 
in the following year after this study However, high-level 
mupirocin resistance was detected among MRSA isolates 
submitted for typing to the Staphylococcal Research Lab- 
oratory, Department of Microbiology, Faculty of Medicine, 
Kuwait University from the burn unit, in November 1996. 
Because MRSA has been a persistent pathogen in the 
burn unit, the observed mupirocin-resistant MRSA could 
have evolved by the acquisition by MRSA already circu- 
lating in the burn unit of a plasmid-borne high level 
mupirocin resistance, which later proliferated, aided by 
mupirocin use. They could also have represented a new 
mupirocin-resistant MRSA clone introduced into the unit 
from outside, probably by a patient, which later spread 
among other patients. To address this question, mupirocin- 
resistant MRSA isolated from patients in the burn unit 
between November 1996 and May 1997 were compared 
with representatives of mupirocin-susceptible MRSA from 
the same unit, using a combination of antibiogram, plas- 
mid analysis, and pulsed-field gel electrophoresis (PFGE). 
MATERIALS AND METHODS 
Methicillin-Resistaut StupbyZococcus aureus 
A total of 53 MRSA isolates were studied. They were 
among MRSA isolated from patients in the burn unit, Ibn 
Sina Hospital, Kuwait, and submitted for typing to the 
Staphylococcal Research Laboratory, Department of 
Microbiology, Faculty of Medicine, Kuwait University. The 
isolates were identified as S. aweus at the Clinical Micro- 
biology Laboratory of Ibn Sina Hospital, Kuwait, by cul- 
tural characteristics, colony morphology, positive results 
for catalase, and tube coagulase test using rabbit plasma 
(Difco Laboratories, Detroit, MD. 
Susceptibility to Antimicrobial Agents 
Susceptibility to antimicrobial agents was tested by the 
disk diffusion method on Mueller-Hinton agar as 
described previously,27 using commercial antibiotic disks 
(Oxoid, Basingstoke, England). Susceptibility to mupirocin 
was determined using disks containing 200 pg and 5 Fg 
of mupirocin. Growth to the edge of the 200-pg 
mupirocin disk indicated high-level resistance, whereas 
growth within a 14-mm zone of inhibition with the 5-p,g 
mupirocin disk detected low-level resistance. Minimum 
inhibitory concentration of mupirocin was determined 
using E-test strips (AB Biodisk, Solna, Sweden), according 
to the manufacturer’s instructions. For testing their sus- 
ceptibility to heavy metals and nucleic acid-binding com- 
pounds, 6-mm disks impregnated with cadmium acetate 
(130 kg), propamidine isethionate (50 Fg), and ethidium 
bromide (60 Fg) were used. Staphylococcus aweus strain 
ATCC25923 was used as the control strain. 
Plasmid Isolation and Transfer 
Plasmids were isolated by the cetyltrimethylammonium 
bromide method, separated by agarose gel electrophore- 
sis and sized as previously described.zs 
Plasmids were transferred in phage-mediated conju- 
gation and conjugation experiments. For phage-mediated 
conjugation experiments, 0.1 mL each of an overnight 
culture of a donor strain and a recipient strain, WBG1876, 
lysogenized with staphylococcal phage J,” was added to 
5.0 mL of Tris-buffered saline @SB) containing 0.01 M 
calcium chloride and incubated at 35°C overnight with 
gentle shaking. The mixture was then pelleted by centri- 
fugation, the supernatant was discarded, and the deposit 
was spread onto selective media containing appropriate 
antibacterial agents. Controls, consisting only of the donor 
and recipient cells were set with the tests. Transfer was 
considered to have occurred when growth was obtained 
from donor-recipient mixtures and not from controls. 
Transcipients were obtained on brain heart infusion agar 
(BHIA) plates containing fusidic acid 5 mg/L, rifampicin 
2.5 mg/L, and one of mupirocin 5 mg/L, chloramphenicol 
10 mg/L, cadmium 60 mg/L, and ethidium bromide 60 
mg/L. Conjugation experiments were performed as pre- 
viously described,29 and transconjugants were obtained 
on selection plates as for the phage-mediated conjuga- 
tion experiment. 
Pulsed-Field Gel Electrophoresis 
Cells were grown overnight in tryptic soy broth and 
used to prepare agarose blocks by a modification of a 
method previously described.29 Then, 1.5 mL of 
overnight culture was centrifuged in a microcentrifuge 
at 2000 times gravity for 5 minutes, and washed twice 
in 1 .O mL of 50 mM EDTA, pH 8.0. The cells were resus- 
pended in 0.5 to 1.0 mL EC buffer (6 n&l Tris; 1 M NaCI; 
100 mM EDTA; Brij 58 [Sigma Chemical, St. Louis, MO, 
USA] 0.5%). Sodium deoxycholate, 0.2%, sodium lam-y1 
sarcosine, 0.5%, pH 7.5, were added to give a cell den- 
sity of approximately 3 X lo8 colony-forming units 
(cfu)/mL. In a fresh microfuge tube, 50 ~.LL of 
lysostaphin, 200 mg/mL, was mixed with 100 p,L of cell 
suspension to which 150 p,L of agarose (chromosomal 
grade, Bio-Rad Laboratories, Richmond, CA, USA) was 
added, mixed, and transferred by pipetting into block- 
forming wells (Bio-Rad) and allowed to solidify. The 
formed blocks were incubated in 1.0 mL EC buffer for 
3 hours, followed by an overnight incubation at 50°C in 
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proteinase K buffer (0.5 M EDTA 5 mM Tris; sodium lau- 
rylsarcosine, l%, pH 7.5) containing 1 mg/mL proteinase 
K. The blocks were then washed in 50 mM EDTA for 2 
hours, with the buffer changed after every 30 minutes, 
and stored at 4°C in 50 mM EDTA. The blocks were 
digested with Sma I (Gibco BRL), according to the man- 
ufacturer’s instructions. Electrophoresis was performed 
with 1% agarose gel in 0.5XTBE buffer, using a CHEF DR 
III apparatus (Bio-Rad Laboratories). The gel was run at 
14”C, 6V/cm and 120°C switch angle for 20 hours. Lin- 
ear ramp of switch times were 0.5 to 40.0 seconds. The 
gels were stained in 0.5 mg/L ethidium bromide and 
photographed under ultraviolet illumination. The chro- 
mosomal patterns were examined and compared by eye 
and assigned to PFGE types. The relatedness of the 
strains was determined according to the recommenda- 
tion of Tenover et aL30 
RESULTS 
Fifty-three MRSA isolates from 34 patients were studied. 
These consisted of 48 mupirocin-resistant and 5 
mupirocin-susceptible isolates. The MRSA were cultured 
from different clinical samples obtained from the throat, 
burn wounds, blood, nose, groin, and axillary (Table 1). 
Resistance to Antimicrobial Agents 
Results of disk susceptibility tests with the mupirocin 
disks revealed that 39 isolates from 26 patients expressed 
mupH and 9 isolates, from 9 patients, expressed mupL. 
Results of MIC determination with E-test strips demon- 
strated that all of the isolates that expressed high-level 
resistance by growing to the edge of 2OOqg mupirocin 
disks, had MICs higher than 1024 pg/mL. The nine iso- 
lates with low-level mupirocin resistance had MICs 
between 32 and 128 pg/mL. Six of them had MICs of 32 
mg/L, two isolates had MICs of 64 mg/L, and one isolate 
had a MIC of 128 mg/L (see Table 1). With regard to their 
susceptibility to other antimicrobial agents tested with 
the disk diffusion method, it was demonstrated that, irre- 
spective of their level of mupirocin resistance, they were 
all resistant to methicillin, penicillin G, gentamicin, 
kanamycin, trimethoprim, cadmium, and mercuric chlo- 
ride, but they were varied in their resistance to strepto- 
mycin, erythromycin, tetracycline, chloramphenicol, 
ciprofloxacin, ethidium bromide, and propamidine 
isethionate. Thirty-three isolates were resistant to strep- 
tomycin, 2 1 were resistant to erythromycin, 47 were resis 
tant to tetracycline, 44 were resistant to chloramphenicol, 
and 47 were resistant to ciprofloxacin. Fifty isolates were 
resistant to propamidine and ethidium bromide. They 
were all susceptible to vancomycin and teicoplanin. 
Because of the similarity of their resistance patterns, 
antibiogram was not an effective typing tool with these 
isolates. 
Table 1. Characteristics of Methicillin-Resistant 
Staphylococcus aureus Isolates 
MRSA 
Patient Isolates Source of Specimens 
Mupirocin- 
Resistant PFGE 
M/C (mg/L) Types* 
1 
2 
9 
10 
11 
12 
13 
14 
15 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
l-7 Canulla sites (2), right hand, HL 1 (7) 
axilla, right & left legs, thigh 
8, IO, 11 Back, nose, burn wound HL I (3) 
9 
12 
13 
14 
15 
16 
17 
18,19 
20 
21-23 
24 
25 
26 
27 
28 
29 
30 
31, 32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47,48 
49 
50 
51 
52 
53 
Right leg 
Nose 
Burn wound 
Left leg 
Throat 
Blood 
Left leg 
Throat, burn wound 
Nose 
Burn wound, groin, left leg 
NS 
Groin 
Right hand 
NS 
Right leg 
Throat 
Face 
Burn wound, nose 
Throat 
Right leg 
Blood 
NS 
Burn wound 
Right thigh 
Burn wound 
Nose 
Axlla 
NS 
NS 
Throat 
NS 
Nose 
NS, burn wound 
Blood 
Throat 
Nose 
Burn wound 
Nose 
HL II 
HL I 
HL I 
$32) I; 
HL I 
HL II 
HL I 
HL II 
HL 1 (3) 
LL (64) I , / 
$32) I! 
S IV 
HL 
LL (32) I! 
HL I 
I 
$64) I 
HL I 
I 
&28) I 
LL (32) Ill 
I 
?:(32) I 
S I 
S 
S 
HL 
HL 
S 
LL (32) I 
HL I 
HL I 
HL I 
HL I 
HL I 
HL II 
*Parentheses: number of isolates with PFGE patterns. MIC = minimum 
inhibitory concentration; HL = high-level resistance; LL = low-level resistance; S 
= mupirocin-susceptible; NS = not specified. Only the MIC of mupL isolates are 
given since the mupH isolates were all over 1024 mg/L. 
Examination of the patients’ medical files revealed 
that 28 of the 34 patients from whom mupirocin-resistant 
isolates were obtained had been treated with mupirocin 
on admission. 
Plasmid Analysis 
The plasmid content of all 53 MRSA isolates is summa- 
rized in Table 2. They harbored three to five plasmids, 
which varied in size between 2.91 kilobases (kb) and 
38 kb. A 38-kb plasmid was present in all mupH isolates 
and absent in the mupL and mupirocin-susceptible iso- 
lates (Figure 1). The other plasmid types were present in 
all of the isolates, irrespective of their level of mupirocin 
resistance, and were not useful in discriminating among 
the isolates. 
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Table 2. Plasmid Contents of Methicillin-Resistant 
Staphylococcus aureus Isolates 
Plasmid HL LL MU/J-S 
Type Plasmid Contents (kb) (n = 39) (n = 9) (n = 5) 
We 1 38, 26, 4.4, 3.3, 2.9 32 - 
Type 2 38, 26, 4.4, 3.3 7 - - 
Type 3 -, 26, 4.4, 3.3, 2.9 - 4 1 
Type 4 -> 26, 4.4, 3.3 - 5 4 
HL = high-level mupirocin-resistant isolates; LL = low-level mupirocin-resistant 
isolates; Mup-S = mupirocin-susceptible. 
Six representative isolates consisting of three with 
mupH and three with mupL were selected and used as 
donors in conjugation and phage-mediated conjugation 
experiments in attempts to isolate the different plasmids 
and determine their resistance phenotypes. High-level 
mupirocin resistance was transferred from all three resis- 
tant isolates (isolates 16,28, and 30) in conjugation exper- 
iments. Transfer of the mupH was accompanied by the 
transfer of the 38 kb plasmid alone or with the cotrans- 
fer of a 4.4 kb plasmid encoding chloramphenicol resis- 
tance when isolates 16 and 30 were used as donors (Table 
3). None of the three mupL isolates transferred any of 
their resistance in conjugation experiments. However all 
six isolates transferred resistance to cadmium, mercuric 
chloride, propamidine isethionate, and ethidium bromide 
in phage-mediated conjugation experiments, and their 
transfer in all instances was accompanied by the transfer 
of a 26 kb plasmid. The plasmids transferred and their 
resistance phenotypes are presented in Table 3. 
Figure 1. Plasmid contents of representative MRSA isolates. Lanes A 
to P contain plasmids from representative MRSA studied. Lane Q con- 
tains plasmids of strain WBG4483 used as size markers. The sizes 
are given in kilobases. Only covalently close circular (CCC) DNA are 
labelled. Chr = chromosomal DNA band. Lanes A, C, D, E, F, I, J, L, 
M, N, and P are representative of the mupH isolates and contain the 
38.kb plasmid; lanes B and G are representative of mupL isolates and 
do not contain the 38.kb plasmid. Lanes K and 0 contain MRSA cor- 
responding to pulsed-field types Ill and IV, respectively. These also lack 
the 38-kb plasmid. 
Table 3. Plasmids Transferred from Mupirocin-Resistant MRSA 
MRSA Mupirocin Mode of Resistance Plasmids 
/so/ate Resistance Transfer* Transferred+ Transferred (kb) 
15 Low P Cd, Hg, Pi, Eb 26 
16 High c Mupirocin 38 
C Cm 4.4 
P Cd, Hg, Pi, Eb 26 
28 Low C Mupirocin 38 
P Cd, Hg, Pi, Eb 26 
30 High c Mupirocin 38 
Cm 4.4 
P Cd, Hg, Pi, Eb 26 
35 Low P Cd, Hg, Pi, Eb 26 
39 Low P Cd, Hg, Pi, Eb 26 
*P = phage-mediated conjugation; C = conjugation; Cd = cadmium; Hg = 
mercuric chloride: Pi = propamidine isethionate; Eb = ethidium bromide; Cm = 
chloramphenicol. 
Pulsed-Field Gel Electrophoresis 
Four pulsed-field patterns, labelled types I to IV, were 
obtained. The PFGE patterns of individual isolates are 
presented in Table 1. Forty-three of the 53 isolates had 
12 34 56 7 
Figure 2. PFGE patterns of representative MRSA isolates. Lane 1 con- 
tains phage lambda concatemer used as size markers. Sizes are in kilo- 
base pairs. Lanes 2 and 5 are representative of PFGE type-l; lane 3, 
PFGE type-Ill; lane 4, PFGE type-l\/; and lane 6, PFGE type-II. Lane 7 
provides size markers. 
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type-1 pulsed-field pattern. This consisted of 34 of the 39 
high-level resistant, 5 of 9 low-level resistant, and 4 of 5 
mupirocin-susceptible isolates. Eight isolates had type II 
pulsed-field pattern consisting of five high-level and three 
low-level mupirocin resistant isolates. The types I and II 
pulsed-field patterns were related but not similar, and dif- 
fered from each other by a total of four DNA bands in the 
50- to lOO-kb fragment region. One type had two DNA 
bands that were absent in the other type (Figure 2). The 
type-111 and type-w pulsed-field patterns consisted of a 
single isolate each. 
DISCUSSION 
This report presents the fist known major incidence of 
high-level mupirocin resistance among S. aureu.s in a 
Kuwait hospital. Until now only three mupirocin-resis- 
tant staphylococci were seen in two hospitals in Kuwait 
(unpublished observation). These consisted of one MRSA 
and two coagulase-negative staphylococci. One of the 
coagulase-negative staphylococci, S. haemolyticus, was 
isolated from a patient in the same burn unit.26 This fmd- 
ing revealing the presence of a major problem with 
mupirocin-resistant MRSA in the burn unit is of concern 
because of its implication for the continued use of 
mupirocin on patients in the burn unit. The findings war- 
rant a review of the protocol for the use of mupirocin in 
the unit. Mupirocin therapy should be given after sus- 
ceptibility testing of MRSA isolates, not only from the 
burn unit but also from other wards in the hospital. 
Although high-level mupirocin resistance in MRSA is still 
low worldwide,l the experience reported here in which 
high-level mupirocin resistance existed in the burn unit 
but was not detected because it was not being tested 
suggests that a similar situation may exist elsewhere. To 
maintain the usefulness of mupirocin therapy, mupirocin 
resistance should be tested for routinely even in facili- 
ties where mupirocin is not being used, because 
mupirocin-resistant MRSA strains can be introduced into 
such facilities, where it can spread among patients. 
Results of transfer experiments demonstrated that 
the 38-kb plasmid in the high-level resistant isolates is a 
self-transmissible plasmid that encodes high-level 
mupirocin resistance. High-level mupirocin resistance has 
been found in self-transmissible and non-self-transmissi- 
ble plasmids in different countries.14~17~23~26 The 4.4-kb 
plasmid encoded chloramphenicol resistance and the 26- 
kb plasmid encoding linked resistance to cadmium, mer- 
curic chloride, propamidine isethionate, and ethidium 
bromide. As none of the plasmids was associated with 
low-level mupirocin resistance, its determinants were 
chromosomal in these isolates, which is consistent with 
other reports that low-level mupirocin resistance genes 
are chromosomal.’ 
Typing of the isolates revealed that they were of dif- 
ferent clones. However, the majority of them were related 
and belonged to PFGE type I and type II. They also had 
similar resistance and plasmid profiles. As shown in Table 
2 and Figure 1, plasmid analysis could identify isolates 
expressing high-level mupirocin resistance because of 
the presence of the 38-kb plasmid in them, but could not 
distinguish those expressing low-level mupirocin resis- 
tance from mupirocin-susceptible isolates. In contrast to 
resistance and plasmid analysis, PFGE typing was more 
discriminatory and demonstrated that the mupH MRSA 
were related to the mupL MRSA and to some mupirocin- 
susceptible MRSA isolated from the same unit. The type- 
I pulsed-field pattern was found among isolates express- 
ing high-level and in those expressing low-level mupirocin 
resistance as well as in mupirocin-susceptible isolates. 
These results suggest that previously mupirocm-suscep- 
tible MRSA circulating in the burn unit had acquired the 
38-kb conjugative plasmid encoding high-level mupirocin 
resistance genes and had spread among different patients, 
its successful maintenance and spread being enhanced by 
mupirocin use. The recovery of mupirocin-resistant iso- 
lates from 28 patients treated with mupirocin supports 
the suggestion that mupirocin use may have enhanced 
their spread. The emergence of mupirocin resistance in 
staphylococci following the prolonged use of the antibi- 
otic has been documented elsewhere.r5,16 However, 
mupirocin-resistant isolates also were recovered from 
patients who had not been treated with mupirocin. These 
patients probably acquired them through cross-contami- 
nation. The similarities in pulsed-field patterns observed 
between mupH and mupL MRSA suggests that the MRSA 
clones acquired both resistance determinants separately. 
They first acquired mupL and later mupH since, in a pre- 
vious study, 5% of the isolates already expressed mupL.26 
The presence of the 26-kb plasmid encoding resistance 
to cadmium, mercuric chloride, propamidine isethionate, 
and ethidium bromide in both mupH and mupL isolates 
further supports the relatedness of the isolates and the 
notion that they evolved from MRSA previously circulat- 
ing in the burn unit. 
The mupH MRSA appeared to have a higher capac- 
ity to spread more readily than the mupL isolates since 
they were isolated more frequently than the mupL iso- 
lates from different body sites in different patients (see 
Table l), reflecting both colonization and infection. This 
could be because the mupH determinant was plasmid- 
borne, and plasmid carriage of resistance may facilitate 
resistance transmission much more easily than chromo- 
somal carriage. Also the presence of different MRSA in the 
same patients would facilitate transfer of the self-trans- 
missible mupirocin-resistance plasmid between the MRSA 
isolates. 
Finally this study has demonstrated the value of a 
central typing laboratory in helping to detect an ongoing 
mupirocin-resistance problem in a burn unit that was not 
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known to exist because it was not being tested for in the 
local hospital laboratory. Routine testing of MRSA for 
mupirocin resistance wiU facilitate early detection of resis- 
tance and can help control the spread of mupirocin-resis- 
tant MRSA. 
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